Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors

RECOMMENDED

Head and Neck Cancer

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT

doi: 10.1016/j.lungcan.2025.108858

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Lung, Respiratory and Thoracic Cancer

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Lung Cancer

Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G

doi: 10.1016/j.lungcan.2025.108762

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Lung, Respiratory and Thoracic Cancer

Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy

Adv Ther

Spira AI, Ran T, Lin I, Chen C, He A, Belani N, Du S

doi: 10.1007/s12325-025-03234-3

Lung, Respiratory and Thoracic Cancer

Real-world evidence of the impact of guideline concordance on survival in non-small cell lung cancer

Lung Cancer

Elter T, Marschall U, Maier PM, Grellmann C, Arnold M, Groß-Ophoff-Müller C, Hoier D, Griesinger F

doi: 10.1016/j.lungcan.2026.109426

COMMENTED

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Curr Oncol

Cheung WY, Lee A, Bote de Cabo H, Burdenski K, Christopoulos P, Pinto-Correia B, Deshayes S, Girard N, Hindocha P, Madden Á, Mella M, Moreira J, Rizzi S, Abreu DR, Soares M, Thomas J, Han M, Calvet CY, Emanuel G, Glassberg MB, Jacobs H, Rault C, Yuan Y, Chouaid C

doi: 10.3390/curroncol33030152

Lung, Respiratory and Thoracic Cancer

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

J Thorac Oncol

Illini O, Hund AC, Kopp HG, Moskovitz M, Mountzios G, Brueckl WM, Früh M, Leßmann ME, Christopoulos P, Stenzinger A, Thomas M, Gillis R, Peled N, Acker F, Addeo A, Charpidou A, Grohé C, Mauti L, Rothschild SI, Schmid S, Schumann C, Urban D, Wurm R, Ekman S, Skribek M, Glanemann F, Wiesweg M, Ackermann CJ, Agelaki S, Hoffknecht P, Jakopović M, Kern J, König D, Kostenzer K, Kropf-Sanchen C, Laack E, Lang D, Nagl L, Pall G, Reck M, Kian W, Allemann AT, Alt J, Araújo D, Bokas A, Hannah F, Julie KJ, Weinlinger C, de Langen AJ, Fergadis EG, Fountzilas E, Froesch P, Frost N, Griesinger F, Jordan F, Karanikiotis C, Kiesewetter B, Korantzis I, Machado AL, Economopoulou P, Pilz A, Reimann P, Rittmeyer A, Saad A, Samitas K, Schulmann K, Shah R, Stratmann JA, Taghizadeh H, Tammoscheit K, Tufman A, Weber JP, Wöll E, Valipour A, Overbeck TR, Hochmair MJ

doi: 10.1016/j.jtho.2026.103651

Lung, Respiratory and Thoracic Cancer

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Transl Lung Cancer Res

Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L

doi: 10.21037/tlcr-24-881

Related content

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy

Real-world evidence of the impact of guideline concordance on survival in non-small cell lung cancer

Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study